ATXS NASDAQ
Astria Therapeutics, Inc.
1W: +1.5%
1M: +3.7%
3M: +73.6%
1Y: +43.1%
3Y: -11.6%
5Y: -8.3%
$12.58
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$112M
-34.4% ▼
Net Income
-$94M
-29.3% ▼
EPS (Diluted)
$-1.68
+30.6% ▲
EBITDA
-$112M
-13.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $26M | $16M | $34M | $57M | $77M |
| SG&A Expenses | $12M | $15M | $20M | $26M | $35M |
| Operating Expenses | $37M | $195M | $54M | $83M | $112M |
| Operating Income | -$37M | -$195M | -$54M | -$83M | -$112M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$37M | -$195M | -$52M | -$73M | -$94M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$37M | -$195M | -$52M | -$73M | -$94M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-12.20 | $-24.58 | $-3.55 | $-2.42 | $-1.68 |
| EBITDA | -$37M | -$30M | -$54M | -$83M | -$112M |
| Shares Outstanding | 3M | 9M | 15M | 30M | 56M |